StoryCommercial
Theranica says US insurance coverage for Nerivio reaches about 130 million lives
A wave of Blue Cross Blue Shield and other payer policies deeming Nerivio medically necessary brought US coverage to roughly 130 million people, which Theranica says rivals major migraine drug classes. The device has been used in more than one million US treatments.
- FDA-cleared for acute and preventive migraine treatment from age 8
- Theranica now headquartered in Bridgewater, New Jersey, with an office in Netanya, Israel